For all new therapeutic antibodies, it is required by regulatory agencies to assess their safety by examining and identifying their potential cross reactivity (TCR) on a panel of 33 normal tissue types from at least three individuals. Following FDA recommendations, we can provide IHC based-TCR examination on: 1. Single tissue sections of 33 normal tissue types on three or more individuals; 2. Low cost TMA of 33 normal tissue types on one individual (MNO341)l; 3. TMA of 33 normal tissue types in duplicates (MNO661); 4. TMA of 33 normal tissue types of three individuals (MNO961 or MNO1021); 5. *Frozen TMA of 33 normal tissue types of one individual (total three sets of TMA from three individuals). �*� � under development.